{"id":"W3011495178","doi":"10.1002/cncr.32811","title":"NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital","funders":"National Cancer Institute; Amgen","keywords":"Bevacizumab; Medicine; Clinical endpoint; Placebo; Gliosarcoma; Progression-free survival; Internal medicine; Phases of clinical research; Surgery; Adverse effect; Glioblastoma; Oncology; Randomized controlled trial; Clinical trial; Overall survival; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006833504,0.0002597879,0.0004767439,0.00005890478,0.00004703057,0.00001833434,0.0001442564,0.00008308013,0.00004035198],"category_scores_gemma":[0.00001353908,0.0001509825,0.00004831517,0.00024253,0.00007895016,0.000009263074,0.00006804182,0.0000865884,6.748092e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003370188,"about_ca_system_score_gemma":0.0001835264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000683941,"about_ca_topic_score_gemma":0.002595032,"domain_scores_codex":[0.998648,0.00005274186,0.0003037355,0.0005106415,0.0002357076,0.000249131],"domain_scores_gemma":[0.9992719,0.000008594585,0.0001947306,0.0002409825,0.0001456341,0.0001381393],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7061828,0.001837406,0.2728502,0.00009981983,0.0006539554,0.00001430581,0.001119074,0.0001798842,0.002893809,0.00000442092,0.0004209528,0.0137434],"study_design_scores_gemma":[0.8196212,0.08672546,0.05775521,0.0003690307,0.000681741,0.000008683096,0.002044499,0.000478391,0.02475876,0.000002184215,0.006287797,0.001267033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970555,0.001266911,0.00004592761,0.00009344121,0.00004717485,0.001365767,0.00004480589,0.000009053355,0.00007137886],"genre_scores_gemma":[0.9991006,0.0001273334,0.00005993931,0.0001524744,0.0001123107,0.0003243175,0.00001383935,0.00003763091,0.00007153168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.215095,"threshold_uncertainty_score":0.6156887,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02214749316887849,"score_gpt":0.3016023983414542,"score_spread":0.2794549051725758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}